Morgan Stanley Downgrades Rocket Pharmaceuticals (RCKT) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Morgan Stanley Downgrades Rocket Pharmaceuticals (RCKT) to Equalweight
May 30, 2025 9:39 AM EDT
Evercore ISI analyst Joshua Schimmer downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Outperform to In Line with a price target of $5.00 (from $18.00).
The analyst comments "Following this weeks sad news that a patient passed away in RCKTs Danon trial, we are... More
May 28, 2025 3:07 PM EDT
JPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Overweight to Neutral with a price target of $7.00 (from $44.00).
The analyst comments "We are downgrading RCKT shares to Neutral from Overweight on the back of yesterdays announced clinical hold on lead program RP-A501... More
May 28, 2025 9:35 AM EDT
Goldman Sachs analyst Richard Law downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Buy to Sell with a price target of $2.00 (from $13.00).
The analyst comments "On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary... More
May 28, 2025 5:13 AM EDT
BofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Rockets announcement of a death in its RP-A501 phase 2 for rare disorder Danon is tragic on... More
